Bristol-myers Squibb Compnay

Myra Beaudoin Bertrand

John E Macor

T G Murali Dhar

Saleem Ahmad

Douglas G Batt

Qingjie Liu

Anurag S Srivastava

Soo Sung Ko

Scott Hunter Watterson

Charles Malcolm Langevine

Qing Shi

Joseph Anthony Tino

George V Delucca

Michael A Galella

David Marcoux

Jingwu Duan

Michael G Yang

Robert J Cherney

Hai-Yun Xiao

Zili Xiao

Yeheng Zhu

Khehyong Ngu

Andrew J Tebben

Lyndon A M Cornelius

Hua Gong

Weiwei Guo

George V De Lucca

Tg Murali Dhar

Carolyn A Weigelt

Lyndon AM Cornelius

Charles M Langevine

Disclosed are compounds of Formula (I) wherein: the two dotted lines represent either two single or two double bonds; Q is: Ris F, Cl, &#x2014;CN, or &#x2014;CH; Ris Cl or &#x2014;CH; Ris &#x2014;C(CH)OH or &#x2014;CHCHOH; Ris H or &#x2014;CH; each Ris independently F, Cl, &#x2014;CH, and/or &#x2014;OCH; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Substituted tetrahydrocarbazole and carbazole carboxamide compounds

There are described ROR&#x3b3; modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR&#x3b3; activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR&#x3b3; activity, for example, autoimmune and/or inflammatory disorders.

Tricyclic sulfones as ROR gamma modulators

There are described ROR&#x3b3; modulators of the formula (I), and formula (II) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR&#x3b3; activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR&#x3b3; activity, for example, autoimmune and/or inflammatory disorders.

Tricyclic sulfones as ROR&#x3b3; modulators

Disclosed are compounds of Formula (I); and salts thereof, wherein: Formula (II); Q is: Ris &#x2014;C(CH)2OH, &#x2014;NHC(=0)C(CH), &#x2014;N(CH3)2, or &#x2014;CHR; Ris CI or &#x2014;CH; Ris H, F, or &#x2014;CH; Ris H or &#x2014;CH; Ris H, F, CI, or &#x2014;OCH3 Ris H or F; and Rd is &#x2014;OH, &#x2014;OCH3, &#x2014;NHC(=0)CH3, or fORMULA (III), Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease. 

Carbazole carboxamide compounds

Growing community of inventors

Lambertville, NJ, United States of America

Myra Beaudoin Bertrand